Boston Scientific Q2 update highlights revenue beat, adjusted EPS growth, and continued medical technology momentum.
Stock Earnings Results
July 29, 2026
Table of Contents
July 29, 2026
Boston Scientific Corporation (NYSE: BSX) reported second-quarter 2026 results above expectations, supported by higher sales, adjusted EPS growth, stronger Cardiovascular performance, broad regional growth, and continued product and clinical progress.
Boston Scientific is a global medical technology company that develops devices and therapies used to diagnose and treat cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases and conditions.
The company reported adjusted EPS of $0.86, above estimates of $0.83, representing a 3.6% earnings surprise. Revenue came in at $5.44 billion, above estimates of $5.39 billion, with revenue growth of 7.5%.
Net sales increased 7.5% year-over-year to $5.44 billion.
Operational and organic sales both increased 7.0%.
GAAP net income attributable to common stockholders was $907 million.
GAAP EPS was $0.61, compared with $0.53 in the prior-year quarter.
Adjusted EPS was $0.86, compared with $0.75 a year earlier.
Boston Scientific said second-quarter sales growth came in at the high end of its guidance range, while adjusted EPS came in above its prior guidance range of $0.82 to $0.84.
Cardiovascular net sales increased 8.3% on a reported basis.
Operational and organic Cardiovascular sales increased 7.8%.
MedSurg net sales increased 5.9% on a reported basis.
Operational and organic MedSurg sales increased 5.4%.
The stronger Cardiovascular performance helped drive overall company growth during the quarter.
U.S. sales increased 6.2%.
EMEA sales increased 6.1% on a reported basis and 4.2% operationally.
Asia-Pacific sales increased 11.2% on both a reported and operational basis.
Latin America and Canada sales increased 22.4% on a reported basis and 16.2% operationally.
The strongest regional growth came from Latin America and Canada, followed by Asia-Pacific.
Boston Scientific invested $1.5 billion in MiRus LLC.
The investment gave Boston Scientific an approximately 34% equity stake and an exclusive option to acquire the MiRus TAVR business.
The company also presented late-breaking findings from the FRACTURE trial for the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter.
Boston Scientific announced positive clinical data for FARAPULSE Pulsed Field Ablation in persistent atrial fibrillation patients who had not previously been treated for the condition.
The company also began enrollment in the pivotal FARADIGM trial for the FARAFLEX Mapping and PFA Catheter.
Boston Scientific completed its previously announced $2.0 billion accelerated share repurchase program.
The company repurchased approximately 40 million shares through the program.
The buyback helped support EPS growth and reflects continued capital return activity alongside product and pipeline investment.
For full-year 2026, Boston Scientific now expects net sales growth of about 5.5% to 6.5% on a reported basis.
Organic net sales growth is expected to be about 5.0% to 6.0%.
Adjusted EPS is expected to range from $3.28 to $3.32.
For the third quarter, the company expects net sales growth of about 3.0% to 5.0% on both a reported and organic basis.
Third-quarter adjusted EPS is expected to range from $0.80 to $0.82.
Boston Scientific delivered another solid medical technology quarter.
Sales beat expectations, adjusted EPS topped estimates, Cardiovascular remained a key growth driver, and regional performance was broad. The company also continued to invest in structural heart, electrophysiology, and minimally invasive technologies while completing a $2.0 billion accelerated share repurchase program.
The key question is whether Boston Scientific can keep converting product innovation and clinical progress into sustained organic sales growth.
Platforms like LevelFields track layoffs, market catalyst, activist investors, leadership changes, dividend increases, margin expansion, and stock reactions together, helping investors identify when healthcare technology stocks are moving on real operating momentum.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE